6. A combination of ado-trastuzumab emtansine and pertuzumab appear to have significant antitumor activity in patients with HER-2–positive breast cancer.
A recent Phase 2a study found that in patients with HER-2–positive, locally advanced breast cancer, a combined regimen of ado-trastuzumab
emtansine yielded significant antitumor activity and an adequate safety profile.
Read more
7. Patients with HER-2–positive, HR-negative breast cancer may achieve a higher rate of complete response with chemotherapy plus neratinib.
A study presented at the American Association for Cancer Research Annual Meeting found that in patients with the HER-2–positive, HR-negative subtype of breast cancer may derive greater benefit from chemotherapy plus
neratinib vs. the standard approach of chemotherapy plus trastuzumab.
Read more
8. Trastuzumab combined with docetaxel and carboplatin may yield favorable results in patients with HER-2–positive disease, without the use of an anthracycline.
A study presented at the 2013 San Antonio Breast Cancer Symposium found that a regimen consisting of trastuzumab combined with the chemotherapy drugs
docetaxel and carboplatin resulted in “excellent” postsurgical results, and was non-inferior to a regimen that included an anthracycline.
Read more
9. PIK3CA mutation may predict pathologic complete response to neoadjuvant treatment in patients with HER-2–positive disease.
In women with HER-2–positive, HR-positive breast cancer, a PIK3CA genetic mutation was independently associated with pathologic complete response to neodjuvant therapy, according to two studies presented at the 2013 San Antonio Breast Cancer Symposium.
Read more
10. In cases of inflammatory or locally advanced HER-2–positive disease, neoadjuvant chemotherapy plus trastuzumab, followed by adjuvant trastuzumab yielded “durable” EFS.
In updated phase 3 results, a higher percentage of patients treated with chemotherapy plus trastuzumab achieved five-year event-free survival than those undergoing chemotherapy alone.
Read more